Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Brain : a Journal of Neurology|March 24, 2022
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Angelo Bellinvia, Mattia Fonderico, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Multiple Sclerosis and Related Disorders|May 8, 2024
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or NatalizumabElisabetta Signoriello, Alessio Signori, Giacomo Lus, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Journal of Neurology|July 5, 2023
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS studyMaria Pia Amato, Roberto Bergamaschi, Diego Centonze, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 7, 2024
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara G Chisari, Umberto Aguglia, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.
Pageof 12